Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …

Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Repeated emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased fitness underscores the value of rapid detection and characterization …

SARS-CoV-2 is an extremely contagious respiratory virus causing adult atypical pneumonia
COVID-19 with severe acute respiratory syndrome (SARS). SARS-CoV-2 has a single …

The unprecedented scale of the ongoing COVID-19 pandemic has catalyzed an intense
effort of the global scientific community to unravel different aspects of the disease in a short …

Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The
active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA …

During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …